Psychoneuroimmunology: Cardiovascular Disease
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Interactions Between Signaling Pathways
Electron Transport Chain: Complex I and II
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Gege Yan1, Zhenbo Han1, Youjeong Kwon1
1Department of Pharmacology and Regenerative Medicine, University of Illinois College of Medicine, Chicago (G.Y., Z.H., Y.K., J.J., S.B.N., X.D., S.P., S.-G.O.).
Ponatinib causes heart damage by disrupting mitochondrial energy production, activating the integrated stress response (ISR) via GCN2. Inhibiting the ISR protects against this cardiotoxicity, offering a potential therapeutic strategy.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: